{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0029515\nAge: 38\nGender: Female\nSample ID: P-0029515-T01-IM6\nGene Panel: IMPACT468\nCancer Type: Invasive Breast Carcinoma\nSample Type: Metastasis\nTumor Purity: 40.0%\n=============\nDNA Variants:\nNUP93 c.43C>T (p.Q15*) - in 7.00% of 421 reads\nNUP93 c.2369G>A (p.R790H) - in 14.00% of 525 reads\nPIK3CA c.3140A>G (p.H1047R) - in 18.00% of 483 reads\nTEK c.1445T>C (p.L482P) - in 15.00% of 662 reads\nCNA Data:\nCCND1 - High Level Amplification\nFGFR1 - High Level Amplification\nWHSC1L1 - High Level Amplification\nPTP4A1 - High Level Amplification\nFGF4 - High Level Amplification\nFGF3 - High Level Amplification\nFGF19 - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}"
}